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Abstract
Background: Early  initiated  antiretroviral  therapy
(aRt) in HIV infected infants leads to improved long-
term viral suppression and survival. Guidelines recom-
mend initiating therapy with a triple aRt consisting of
two  nucleoside  reverse  transcriptase  inhibitors  (nR-
tIs) and either one additional non-nucleoside reverse
transcriptase  inhibitor  (nnRtI)  or  a  protease  in-
hibitor (PI). compared to older children and adults,
viral relapse is seen more frequently in infants receiv-
ing triple aRt. We now address the possibility of a
more  potent  aRt  with  a  quadruple  induction  and
triple maintenance therapy. 
Methods: We examine the longitudinal course in four
HIV  infected  infants,  who  were  referred  from  other
centers and could not be recruited to multicentre trials.
We introduced aRt initially consisting of two nRtIs,
one nnRtI and one PI and later discontinued the PI
at the age of 12 months maintaining a triple regime
consisting of two nRtIs and one nnRtI. 
Results: Provided  that  therapy  adherence  was  main-
tained we observed an effective sustained decline of
viral load and significant cd4 cell reconstitution even
after switching to a triple regime. no drug associated
toxicity was seen. 
Conclusion: We suggest that a four drug therapy might
be a possible initial therapy option in HIV infected in-
fants, at least in those with a high viral load, followed
by  a  maintenance  triple  regime  after  12  months  of
therapy.
Key words: HIV, HaaRt, anti HIV agents, infants, vi-
ral load
BacKGRound
European  [1]  and  us  guidelines  [2]  recommend  to
start with aRt in all HIV infected infants below the
age of 12 months irrespective of clinical or immuno-
logical stage. In particular, in infants infected despite
attempted  mother  to  child  transmission  prophylaxis,
aRt should be commenced as soon as the diagnosis is
confirmed. Evidence that early therapy in all infected
infants leads to a significant reduction of morbidity
and mortality compared to deferring treatment came
from cHER trial conducted in south africa [3] and
from the European Infant collaboration group [4]. In
the cHER trial early HIV diagnosis and early treat-
ment reduced early infant mortality by 76%.
Virological failure continues to be a major challenge
after  initiating  early  aRt  in  infants.  PEnPact-1
showed recently that in children following the recom-
mended  initial  regimen  with  two  nucleoside  reverse
transcriptase inhibitors (nRtI) and one protease in-
hibitor (PI) or non-nucleoside reverse transcriptase in-
hibitor (nnRtI) 71% were on first-line aRt after a
median follow-up time of 5 years, nevertheless only
56% had continued viral load suppression [5]. Previ-
ous studies even show that consistent long term viral
suppression with HIV-1 Rna below detection limit is
achieved in less than 50% of the children with first
line triple aRt.. children with an increased viral load
are at risk for a rapid progression of disease and thera-
py failure [6, 7]. While this drug combination follows
official recommendations [1, 2], several studies have
addressed  the  possibility  of  introducing  a  more  ag-
gressive initial regime consisting of four antiretroviral
drugs [8-13]. 
luzuriaga et al studied 52 infants receiving different
therapy regimes and demonstrated an improved long-
term  viral  suppression  in  patients  with  a  quadruple
therapy initiated before the age of 3 months [9]. a tol-
erability and safety study showed low adverse events in
children receiving a 4- and 5- drug regimen [10]. Based
on these findings and our own experience with stan-
dard triple aRt we report on four vertically HIV in-
fected  children,  in  whom  a  quadruple  antiretroviral
drug scheme was introduced consisting of two nRtIs,
one nnRtI and one PI. We furthermore address the
possibility of starting with a quadruple therapy in the
first year of life and later maintaining a triple regime
consisting of two nRtIs and one nnRtI.
MEtHods
PatIEnts
Between  2004  and  2009  four  infants  were  initially
treated with a quadruple therapy at our HIV outpa-
tient clinic. all were referred to us from other centers.
all mothers underwent a caesarean section. In two pa-
tients, maternal HIV diagnosis was made at a late stage
Eur J Med Res (2011) 16: 243-248 ﾩ I. Holzapfel Publishers 2011
InductIon MaIntEnancE concEPt foR HaaRt as InItIal
tREatMEnt In HIV InfEctEd Infants
s. Ghosh1*, J. neubert1*, t. niehues2, o. adams3, n. Morali-Karzei1, a. Borkhardt1, H. J. laws1
1department of Pediatric oncology, Hematology and clinical Immunology, Heinrich-Heine universit￤t d￼sseldorf, 
Medical faculty, duesseldorf, Germany
2department of Pediatrics, Helios Hospital Krefeld, Krefeld, Germany
3Institute of Virology, Heinrich-Heine universit￤t d￼sseldorf, d￼sseldorf, Germany
* Both authors contributed equally to this work.
1) Ghosh_Umbruchvorlage  03.06.11  17:12  Seite 243of  pregnancy,  thus  transmission  prophylaxis  to  pre-
vent mother to child infection was incomplete. In both
children HIV infection was revealed after birth; in pa-
tient 1 at the age of 4 weeks, in patient 2 at the age of
5 months. In mothers of patient 3 and 4 a caesarean
was  performed  due  to  obstetric  problems.  Maternal
HIV was not diagnosed until after birth, when their
children were admitted due to repeated watery wast-
ing-syndrome-like diarrhea, failure to thrive and pneu-
mocystis  jiroveci  pneumonia.  for  detailed  patient
characteristics  see  table  1.  after  discharge,  patients
were followed at least once to twice monthly, before
they  were  switched  to  a  trimonthly  interval,  once  a
good viral control was achieved. Prophylaxis of op-
portunistic  infections  included  trimethoprim-sul-
famethoxazole (patients 1,2,4), atovaquon (patient 3)
and  i.v.  immunoglobulines  (patient  3-4)  in  the  chil-
drens’ first year of life.
antIREtRoVIRal dRuGs
In all patients we introduced a regimen consisting of
two nRtIs, one nnRtI and one PI. In the light of
existing literature that quadruple therapy might have a
positive effect on initial viral load without any major
adverse consequences our studies strongly conformed
to the Helsinki declaration. Informed consent regard-
ing implementing a quadruple drug regimen and publi-
cation of anonymized data was obtained from all par-
ents. In patient 1 resistance testing was carried out,
which did not imply any drug restrictions. antiretrovi-
ral drugs used for therapy were given at the following
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Table 1. Patient characteristics.
Patient 1234
Mode of delivery caesarean (38th week) caesarean (29th week) caesarean caesarean (41st week)
Prepartal  ZdV, 3tc, nVP none none none
prophylaxis (5 weeks)
Intrapartal  ZdV none none none
prophylaxis 
Postnatal  ZdV (4 weeks) 2 x nVP; ZdV +  none none
prophylaxis 3tc (6 weeks)
age at diagnosis 4 weeks 5 months 2.5 months 4.5 months
Initial HIV-1 Rna 500 000 16 000 139 670 3 600 000
load (copies/ml)
Initial cd4 cell  3732 / 44 2515 / 43 1093 / 17 330 / 6
count (absolute 
cells, μl / %)
Initial cd4 cell  106 100 44 13
count (aRP, %)
4 drug HAART ABC, 3TC, LPV,  ABC, 3TC, LPV,  ZDV, 3TC, NFV,  ZDV, 3TC, LPV, 
NVP NVP NVP NVP
Maximal decline  5 log; 4.5 months 4 log; 2 months 5 log; 2 months 5 log; 6 months
of viral load (log 
change and duration)
duration of 4  11 months 13 months 13 months 10 months
drug HaaRt
clinical toxicity *atopic dermatitis none none none
laboratory toxicity AST (1.4 x uln  AP (1,4 x uln - AP (1,2 x uln –  AP (1.8 x uln -
- Grade 1); Grade 1); Grade); CK (2.2  Grade 1);
AP (2.2 x uln  ▲ CK (4.2 x  x uln – Grade  CK (2.4 x uln -
-Grade 1);  uln - Grade 1); 0), *GGT (7.2 x  Grade 0);
Cholesterol (235  *GGT (2.1 x  uln) *GGT (27 x 
mg/dl – Grade 2);  uln) uln);
*GGT (18.6 x  Triglycerides (498 
uln) mg/dl - Grade 1)
3 drug HAART ABC, 3TC, NVP ABC, 3TC, NVP ZDV, 3TC, NVP ZDV, 3TC, NVP
Viral load at  16801 <1 <1 48
last visit (copies/ml)
follow up time 50 months 50 months 34 months 27,5 months
Antiretroviral drugs: abacavir (aBc), lamivudine (3tc), lopinavir (lPV), nelfinavir (nfV), nevirapine (nVP), Zidovudine
(ZdV); adverse effects were graded according to daIds (division of aIds, nIH), uln = upper limit of normal, *no
daIds criteria; ▲elevated 4 weeks after switching to a triple drug regime
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face area, twice 150-200mg of nVP/mﾲ, twice 300mg
of lPV/mﾲ (increased due to addition of nVP), twice
55mg of nfV/kg body weight, twice 8mg of aBc/kg
, twice 4mg of 3tc/kg. adverse effects were graded
according to daIds (division of aIds, nIH) [14].
therapeutic drug monitoring was applied in patient 1
as  viral  relapse  in  this  patient  suggested  malcompli-
ance. 
PlasMa HIV-1 Rna, dEtERMInatIon of
lyMPHocytE suBsEts By floW cytoMEtRy and
laBoRatoRy analysIs
Plasma viral load was determined by quantitative PcR,
the  lower  limit  of  detection  of  the  assay  was  50
(Quantiplex  3.0  HIV-Rna,  chiron,  fernwald  Ger-
many) and 40 (m2000rt Realtime HIV-1 assay, abbott
laboratories, abbott Park, Il) HIV1-Rna copies/ml
in plasma. cd4 cells were measured with routine flow
cytometry (facscalibur, Bd) applying the following
conjugated anti-human mabs: cd8- fluorescein-isoth-
iocyanat, cd4- phycoerythrin, cd3- peridinin chloro-
phyll protein (Becton dickinson, Bridgeport, nJ). ab-
solute cd4 t cell numbers were related to age and
age-related percentages (aRP) were calculated as pub-
lished [15]. Routine clinical chemistry was performed
to determine adverse effects according to daIds.
REsults
therapy was initiated in four children as seen in table
1. In all patients quadruple treatment was initiated im-
mediately after they were seen at our department for
the first time and diagnosis was made (range: 4 weeks
to 5 months). all patients have been seen at our de-
partment in regular intervals. two children have nearly
reached the age of five [mean time of follow up: 42
months, range: 27,5 months - 50 months]. 
VIRoloGIcal REsPonsE
all patients experienced a tremendous decrease of viral
load. In all patients we observe a viral load below 500
copies/ml within a mean time of 2.25 months of thera-
py. all patients had a significant decline in viral load (4-
5 log10 within 6 months of therapy) and three patients
had a viral load below level of detection within a mean
time  of  two  months  (fig.  1).  switching  to  a  triple
regime was not followed by a viral relapse. However, in
EuRoPEan JouRnal of MEdIcal REsEaRcH June 21, 2011 245
Fig. 1. Peripheral blood viral load (copies/ml) and cd4 count (age related percentage) over time in infants with antiretroviral
therapy. the upper horizontal bars show the quadruple and triple drug regime of each patient over time. the horizontal dotted
line in each graph represents 100% of age related cd4 cells.
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of  20  months.  therapeutic  drug  monitoring  showed
that non-compliance has been the major factor for viral
failure. In patient 3 we even see a HIV seroreversion
[16] as published. thus all patients remain at the initial
antiretroviral regime, as viral load is sustaining. 
clInIcal folloW-uP
Patient 1 and 2 were in a good clinical condition, as
the diagnosis was established due to a known maternal
HIV infection, while in patients 3 – 4 HIV was diag-
nosed,  when  they  were  admitted  due  to  a  critical
aIds-defining condition. after introducing quadruple
therapy  both  patients  experienced  a  profound  im-
provement of the general condition. till now all pa-
tients remain free of further acquired aIds defining
conditions or severe illness. 
IMMunREconstItutIon
absolute cd4 cells and cd4 age-related-percentages
(see fig. 1) in patient 1 and 2 have been initially within
the estimated range and hence no long-term change
was observed. Patient 3 and especially patient 4, suf-
fering from a seriously depleted cd4 cell count (40%
and  20%  of  age-related-percentages),  experienced  a
reconstitution (4.5 months in patient 3, 12 months in
patient 4) during the observation period (> 100% age-
related-percentage).
safEty
Quadruple therapy was well tolerated in all patients.
all patients gained weight and height. Patient 1 devel-
oped  atopic  dermatitis;  in  patient  3  seborrhoic  der-
matitis,  which  already  begun  before  aRt,  was  sus-
tained under treatment. We did not observe any major
drug toxicity in any patient. a slight elevation of crea-
tine kinase (patient 2,3,4), triglycerides (patient 4), to-
tal cholesterol (patient 1), aspartate transaminase (pa-
tient 1), alanine transaminase (patient 1), gamma-glu-
tamyl transferase (patient 1,2,3,4) and alkaline phos-
phatase (patient 1,3,4) were reported. no treatment re-
lated adverse clinical or laboratory event grade 3 or 4
was seen while the patients were receiving a four drug
combination.
In all patients four antiretroviral drugs for a defined
period led to a rapid decline in viral load, which, pro-
vided  drug  compliance  was  given,  sustained  for  the
whole  observation  time,  even  after  switching  to  a
triple regime. In all patients cd4 cells reconstituted to
normal values and all patients were free from aIds
defining conditions afterwards. Even after a mean time
of observation of 42 months we did not see any po-
tential long time side effect, which can be attributed to
a 4-drug therapy.
dIscussIon
In HIV infected children mortality and disease pro-
gression is especially high in infancy [6, 7]. children
with an increased viral load, especially those with an
aIds defining illness, are at risk for rapid progression
and death, even after starting aRt [6, 7]. Most studies
published to date suggest that long term control of vi-
ral replication is difficult to achieve in children espe-
cially  in  infants  starting  early  aRt.  the  PEnta  7
study with 20 infants showed a rapid decrease in viral
load within four weeks, however only 25% achieved a
viral load below the level of detection (20% after 24
weeks  of  therapy)  [6].  a  96-week  follow  up  in  the
PEnta 7 study shows that only 55% of the children
still received the initial aRt regimen. chiappini et al
reported on 40 perinatally HIV-infected children re-
ceiving HaaRt with a median follow up of 5.96 years
and observed that 77.5% of the early treated children
had undetectable viral load at their last visit, however
only 47,5% were still receiving their first HaaRt regi-
men [17, 18].
due  to  this  frequently  observed  virologic  failure
several studies have addressed the possibility of intro-
ducing a more aggressive initial regime consisting of
four  antiretroviral  drugs  however  only  few  authors
have compared 3- with 4-drug regimens.
luzuriaga  compares  three  different  combinations
(ZdV+3tc+nVP vs ZdV+3tc+nVP+abacavir(aBc)
vs.  3tc+nVP+stavudine(d4t)+nelfinavir(nfV))  in
children below and above 3 months of age at the time
of initiation (n = 52) [9]. a significant difference in an
intention-to-treat  analysis  was  seen  in  week  48  and
week  200  between  both  reverse  transcriptase  in-
hibitors only regimen (nRtI and nnRtI) on the one
hand and the quadruple drug regimen consisting of a
nRtI, a nnRtI and a PI on the other. an increased
toxicity was not reported. studies conducted in adults
comparing a triple therapy (2 nRtIs 1 nnRtI) with a
quadruple therapy (3 nRtIs 1 nnRtI) did not show
any  significant  difference  leading  to  the  conclusion
that an additional drug class is required to see any su-
periority [8, 11].
starr observed 57 children (range 3.8 to 16.8 years),
who were previously treated with nRtIs, switching to
a regimen consisting of two nRtIs+nfV+efavirenz
(EfV)  [12].  no  control  groups  were  analyzed.  the
percentage of patients with a low viral load increased
rapidly under the new combination and remained sta-
ble from week 8 to week 48. at week 48, the percent-
age of children with plasma HIV-1 Rna levels of less
than 400 copies per milliliter was 81 percent, the ab-
solute percentage of cd4 cells had increased by a me-
dian of 3 percent.
Melvin  observed  36  children  (range  0.2  to  16.0
years) with different previous drug combinations be-
fore changing to a four or even five drug regimen [10].
after initiation of the new regimen all children experi-
enced a significant decrease in viral load. the median
Rna level at the last follow-up during 4- or 5-drug
aRt was 1.7 log10, 78% of the children had Rna lev-
els below the level of detection. after a median of 29
months of 4- or 5-drug aRt, the median cd4 cell
count  had  an  increase  by  339  cells/ﾵl.  cd4  cell
counts  improved  to  or  remained  at  age-appropriate
levels  in  children  with  a  viral  load  below  50
copies/ml.
In the above mentioned studies the patients were
kept on their 4- or 5-drug aRt despite achieving un-
detectable viral load. since long term side effects of
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infants starting with early aRt we initially treated the
4 infants with a quadruple aRt consisting of two nR-
tIs, one nnRtI and one PI and then switched to a
triple maintenance therapy with two nRtIs and one
nnRtI  after  achieving  significant  viral  suppression
and immune reconstitution. In our patients receiving a
quadruple therapy a rapid and significant reduction of
viral load was seen within 2 months of therapy. all pa-
tients achieved a viral load below < 500 copies / ml
within 6 months, in ﾾ patients viral load was below
detection limit within 2 months. Even after changing
to a triple regimen all patients are still on their initial
aRt regimen and only one patient experiences a viral
relapse due to proven malcompliance.
Beside slightly elevated biochemical parameters no
grade 3 / 4 toxicity was observed and medication was
well-tolerated.  In  treatment  naive  infants  luzuriaga
described adverse clinical or laboratory events in 8 of
52 patients receiving quadruple therapy (grade 2 (4 pa-
tients), grade 3 (1 patient), grade 4 (3 patients)), how-
ever these patients were receiving reverse-transcriptase
inhibitors only (2 nRtI + 2 nnRtI); while no treat-
ment-related adverse effect was reported among chil-
dren receiving the regimen including a PI (2 nRtI + 1
nnRtI + 1 PI) [9]. In therapy-experienced children
receiving a four drug regimen adverse reactions were
limited to mild neutropenia and mild transient eleva-
tions in liver enzymes [10]. starr observed severe ef-
fects, consisting of severe neutropenia, hepatic toxici-
ty, diarrhea and rash with fever, in about 10% of the
children  treated  with  two  nRtIs  and  two  nnRtIs
[12]. 
though not observed in our patients theaddition of
another drug class in HIV initial treatment could im-
ply the possibility of further interactions and adverse
effects with the co-medication regarding prophylaxis
and  therapy  of  opportunistic  infections.  Inadequate
plasma drug levels due to malabsorption or non-ad-
herence lead to development of drug resistance which
preserves only few alternatives for further treatment.
We treated four children with a 4 drug combination
for 10-13 months. While two children received an in-
complete  peripartal  prophylaxis  and  were  thus  pre-
treated, in two patients HIV was diagnosed during an
opportunistic infection. Both subgroups strongly qual-
ified for a virologic relapse. three out of four patients,
who were initially treated with a 4 drug combination
for  12  months  showed  sustained  virus  suppression
and  did  not  relapse  even  after  changing  to  a  triple
therapy with two nRtI and one nRtI. In one patient
who initially had viral load below detection limit after
4.5 months of therapy, viral rebound later occurred
and  was  related  to  adherence  problems,  concluding
that in all adherent patients viral load remained low.
compared to other studies and our own experience in
the past with triple aRt, treatment failure and resis-
tance is common on triple aRt and was improved on
a  quadruple  drug  regimen.  drug  toxicity  is  not  in-
creased as seen in our patients. a quadruple induction
therapy is still not recommended in all current guide-
lines, but since a high viral burden and opportunistic
infections at the time of diagnosis predict an unfavor-
able outcome, we strongly support a quadruple thera-
py in these patients. as we consider that the first year
of life represents the most vulnerable phase a 4 drug
regime should be maintained for this period. drug lev-
els and viral load should be monitored at close inter-
vals.  clinical  trials  with  larger  pediatric  cohorts  and
different  combinations  are  strongly  required  to  ad-
dress this question and to provide essentials for a new
definition and composition of a “highly active anti-
retroviral therapy”. 
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